We need many kind of such revolutions. See Ignyta (RXDX) for example:
So the drug, RXDX-105, only works for a part of RET fusions. But if it's a non-KIF5B-RET fusion, then it appears to work quite well.
Commercially, in terms of numbers, some targeted therapy directed to EGFR in NSCLC would grab quite a large share of the market. We had discussed AZN's FLAURA here on the forum
Well, and then there is the whole space beyond individual mutations. IDRA had some results at ESMO which some people on Twitter opined to be a confirmation of TLR 9 agonists and by this supporting DVAX SD101 (one such TLR 9 agonist).
Ahh. And if you're more venture capital oriented, this platform company would have been interesting http://rigontec.com/ (RIG-I ... somewhat related to TLR in the chain of effects, but I am a layman to explain better) ... however, it was just bought by MRK.
... too few hours in the day to follow everything, sigh.
I completely lost track of MRTX and I guess this prior news accounts for the recent sharp turnaround in shares. Do you see any warts in this prior data or do you see it as fairly encouraging?